Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11221217 | 0.85 | ALDH1A1 (0.53) | KMT2AKDM4EMAPTRECQLALDH1A1 | |
| SCHEMBL11227821 | 0.84 | ALDH1A1 (0.50) | KMT2AKDM4EMAPTRECQLALDH1A1 | |
| SCHEMBL11223679 | 0.81 | ALDH1A1 (0.52) | KMT2AKDM4EMAPTALDH1A1POLB | |
| SCHEMBL11213958 | 0.81 | KMT2A (0.56) | KMT2AKDM4EMAPTALDH1A1POLB | |
| SCHEMBL11215076 | 0.80 | KMT2A (0.55) | KMT2AKDM4EMAPTALDH1A1POLB | |
| SCHEMBL11216635 | 0.80 | KMT2A (0.55) | KMT2AKDM4EMAPTALDH1A1POLB | |
| SCHEMBL11206183 | 0.79 | ALDH1A1 (0.60) | KMT2AKDM4EMAPTALDH1A1POLB | |
| SCHEMBL11214982 | 0.78 | ALDH1A1 (0.62) | KMT2AKDM4EMAPTRECQLALDH1A1 | |
| SCHEMBL6000133 | 0.76 | ALDH1A1 (0.67) | KMT2AKDM4EMAPTALDH1A1POLB | |
| SCHEMBL11668425 | 0.76 | MGLL (0.77) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4349685-A | 5-Substituted-benzoxathiol-2-ones | THE DOW CHEMICAL COMPANY (US) | 1982-09-14 | — | — | US | claimed |
| US-20060234987-A1 | Neuroprotective benzo 1 3 oxathiol 2 ones | JAQUITH JAMES B | 2006-10-19 | — | — | US | disclosed |
| WO-2005012281-A1 | NEUROPROTECTIVE BENZO[1,3]OXATHOL-2-ONES | AEGERA THERAPEUTICS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
| US-4349685-A | 5-Substituted-benzoxathiol-2-ones | THE DOW CHEMICAL COMPANY (US) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234987-A1 | Neuroprotective benzo 1 3 oxathiol 2 ones | NLN, SMN1; SMN2, TXN2 | KMT2A 4306/4885KDM4E 4418/4885MAPT 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.